Scientists Sent Viruses to Kill Bacteria. Then They Gave the Viruses CRISPR.

The answer, based on the data: yes, it appears to be.

No serious adverse events were reported in any of the SNIPR001 dose groups. The rate of side effects wasn't significantly different from placebo. And the broader gut microbiome stayed intact, which matters enormously. One of the biggest problems with traditional antibiotics is that they're like carpet-bombing a city to take out one building. SNIPR001, by contrast, acted more like a guided missile.

It Stayed Where It Was Supposed To

One of the most reassuring findings involves where the therapy ended up in the body. Functional SNIPR001 was recovered from stool samples in dose-proportional concentrations (higher dose, more phage detected). But it was not meaningfully found in blood or urine.

That's a big deal. It means these engineered phages stayed confined to the gastrointestinal tract, doing their job exactly where they were designed to work, without wandering off into the rest of the body. For a therapy built on gene-editing technology, that kind of containment is the difference between reassuring regulators and terrifying them.

At the highest dose, researchers observed a 78% reduction in gut E. coli levels compared to placebo. That reduction didn't hit statistical significance in this small trial, but the directional signal was clear.

Why This Matters Beyond the Lab

So who actually needs a CRISPR-armed phage aimed at gut E. coli? Cancer patients, for starters.

People undergoing hematopoietic stem-cell transplants (basically, bone marrow transplants) for blood cancers have severely weakened immune systems. E. coli living in their gut can escape into the bloodstream, causing life-threatening infections. If you could selectively wipe out that E. coli before the transplant without nuking the rest of the microbiome, you'd potentially save lives.

That's exactly what SNIPR Biome is testing next. The company has launched a Phase 1b trial across eight U.S. centers, targeting 24 hematological cancer patients undergoing transplants. Recruitment is already more than halfway complete.

Christian Grøndahl, CEO and co-founder of SNIPR Biome, highlighted the Phase 1b progress, emphasizing the potential to reduce E. coli bloodstream infection risk in these vulnerable patients. Eric van der Helm, the company's VP of Business Development, Bioinformatics & Lab Automation, called the Phase 1 results a "major milestone" that validated the therapy's safety profile, gut restriction, and CRISPR-enabled precision.

The Bigger Picture: Phages Are Having a Moment

SNIPR Biome isn't working in isolation. The phage therapy field has been quietly building momentum. Companies like Armata Pharmaceuticals, Adaptive Phage Therapeutics, and Locus Biosciences are all pushing engineered phages toward the clinic.

But SNIPR001 represents something genuinely new: the first published human safety data combining phage therapy with CRISPR gene editing. It's proof that the concept works in living, breathing people without causing harm.

Regulatory agencies are paying attention, too. The FDA has been "supportive" of phage development, enabling access through expanded access programs for life-threatening cases. The EMA has also been developing guidelines for bacteriophage products. The regulatory ice is thawing.

What Comes Next

Let's be honest about what we don't know yet. This was a tiny trial in healthy people. The therapy's actual clinical benefit (does it prevent infections in sick patients?) remains unproven. The 78% E. coli reduction at the highest dose is encouraging but not statistically significant. And the leap from 36 healthy volunteers to cancer patients with compromised immune systems is a big one.

SNIPR Biome also received just $3.9 million from CARB-X back in 2021 to develop SNIPR001, which is modest funding for a platform this ambitious. Scaling up production of engineered phage cocktails, navigating complex regulatory pathways, and proving efficacy in larger trials will require significantly more capital.

But the foundation has been laid. For the first time, scientists have shown that you can take a century-old concept (using viruses to kill bacteria), upgrade it with 21st-century gene-editing technology, put it in a pill, give it to humans, and have it work safely where it's supposed to.

In a world where bacteria are evolving faster than our antibiotics can keep up, that's not just a scientific milestone. It's a glimpse of how we might actually fight back.

The FDA Wants Fake Brain Surgery Before It'll Approve This Gene Therapy

The FDA told uniQure its promising Huntington's gene therapy needs a sham brain surgery trial before approval, torching the stock by 40%. The resulting ethical and regulatory showdown could reshape the future of every gene therapy that targets the brain.